▶ 調査レポート

経皮スコポラミンの世界市場(~2026年)

• 英文タイトル:Global Transdermal Scopolamine Market Insights and Forecast to 2026

QYResearchが調査・発行した産業分析レポートです。経皮スコポラミンの世界市場(~2026年) / Global Transdermal Scopolamine Market Insights and Forecast to 2026 / MRC2-11QY10790資料のイメージです。• レポートコード:MRC2-11QY10790
• 出版社/出版日:QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、113ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療、製薬
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料は経皮スコポラミンのグローバル市場について調査・分析したレポートです。種類別(錠剤タイプ、シロップタイプ、注射タイプ、パッチタイプ、ジェルタイプ)市場規模、用途別(病院、診療所、救急車センター、その他)市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別経皮スコポラミンの競争状況、市場シェア
・世界の経皮スコポラミン市場:種類別市場規模 2015年-2020年(錠剤タイプ、シロップタイプ、注射タイプ、パッチタイプ、ジェルタイプ)
・世界の経皮スコポラミン市場:種類別市場規模予測 2021年-2026年(錠剤タイプ、シロップタイプ、注射タイプ、パッチタイプ、ジェルタイプ)
・世界の経皮スコポラミン市場:用途別市場規模 2015年-2020年(病院、診療所、救急車センター、その他)
・世界の経皮スコポラミン市場:用途別市場規模予測 2021年-2026年(病院、診療所、救急車センター、その他)
・北米の経皮スコポラミン市場分析:米国、カナダ
・ヨーロッパの経皮スコポラミン市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの経皮スコポラミン市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の経皮スコポラミン市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの経皮スコポラミン市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Baxter International Inc.、GlaxoSmithKline plc、Novartis AG、Perrigo Company plc.、Caleb Pharmaceuticals, Inc.、Myungmoon Pharma Co. LTD.
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Market Analysis and Insights: Global Transdermal Scopolamine Market
The global Transdermal Scopolamine market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Transdermal Scopolamine Scope and Market Size
Transdermal Scopolamine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Transdermal Scopolamine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Transdermal Scopolamine market is segmented into
Tablet Type
Syrups Type
Injections Type
Patch Type
Gel Type

Segment by Application, the Transdermal Scopolamine market is segmented into
Hospital
Clinic
Ambulance Center
Others

Regional and Country-level Analysis
The Transdermal Scopolamine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Transdermal Scopolamine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Transdermal Scopolamine Market Share Analysis
Transdermal Scopolamine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Transdermal Scopolamine business, the date to enter into the Transdermal Scopolamine market, Transdermal Scopolamine product introduction, recent developments, etc.

The major vendors covered:
Baxter International Inc.
GlaxoSmithKline plc
Novartis AG
Perrigo Company plc.
Caleb Pharmaceuticals, Inc.
Myungmoon Pharma Co. LTD.

レポート目次

1 Study Coverage
1.1 Transdermal Scopolamine Product Introduction
1.2 Market Segments
1.3 Key Transdermal Scopolamine Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Transdermal Scopolamine Market Size Growth Rate by Type
1.4.2 Tablet Type
1.4.3 Syrups Type
1.4.4 Injections Type
1.4.5 Patch Type
1.4.6 Gel Type
1.5 Market by Application
1.5.1 Global Transdermal Scopolamine Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Ambulance Center
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Transdermal Scopolamine Market Size, Estimates and Forecasts
2.1.1 Global Transdermal Scopolamine Revenue 2015-2026
2.1.2 Global Transdermal Scopolamine Sales 2015-2026
2.2 Global Transdermal Scopolamine, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Transdermal Scopolamine Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Transdermal Scopolamine Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Transdermal Scopolamine Competitor Landscape by Players
3.1 Transdermal Scopolamine Sales by Manufacturers
3.1.1 Transdermal Scopolamine Sales by Manufacturers (2015-2020)
3.1.2 Transdermal Scopolamine Sales Market Share by Manufacturers (2015-2020)
3.2 Transdermal Scopolamine Revenue by Manufacturers
3.2.1 Transdermal Scopolamine Revenue by Manufacturers (2015-2020)
3.2.2 Transdermal Scopolamine Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Transdermal Scopolamine Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Transdermal Scopolamine Revenue in 2019
3.2.5 Global Transdermal Scopolamine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Transdermal Scopolamine Price by Manufacturers
3.4 Transdermal Scopolamine Manufacturing Base Distribution, Product Types
3.4.1 Transdermal Scopolamine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Transdermal Scopolamine Product Type
3.4.3 Date of International Manufacturers Enter into Transdermal Scopolamine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Transdermal Scopolamine Market Size by Type (2015-2020)
4.1.1 Global Transdermal Scopolamine Sales by Type (2015-2020)
4.1.2 Global Transdermal Scopolamine Revenue by Type (2015-2020)
4.1.3 Transdermal Scopolamine Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Transdermal Scopolamine Market Size Forecast by Type (2021-2026)
4.2.1 Global Transdermal Scopolamine Sales Forecast by Type (2021-2026)
4.2.2 Global Transdermal Scopolamine Revenue Forecast by Type (2021-2026)
4.2.3 Transdermal Scopolamine Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Transdermal Scopolamine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Transdermal Scopolamine Market Size by Application (2015-2020)
5.1.1 Global Transdermal Scopolamine Sales by Application (2015-2020)
5.1.2 Global Transdermal Scopolamine Revenue by Application (2015-2020)
5.1.3 Transdermal Scopolamine Price by Application (2015-2020)
5.2 Transdermal Scopolamine Market Size Forecast by Application (2021-2026)
5.2.1 Global Transdermal Scopolamine Sales Forecast by Application (2021-2026)
5.2.2 Global Transdermal Scopolamine Revenue Forecast by Application (2021-2026)
5.2.3 Global Transdermal Scopolamine Price Forecast by Application (2021-2026)

6 North America
6.1 North America Transdermal Scopolamine by Country
6.1.1 North America Transdermal Scopolamine Sales by Country
6.1.2 North America Transdermal Scopolamine Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Transdermal Scopolamine Market Facts & Figures by Type
6.3 North America Transdermal Scopolamine Market Facts & Figures by Application

7 Europe
7.1 Europe Transdermal Scopolamine by Country
7.1.1 Europe Transdermal Scopolamine Sales by Country
7.1.2 Europe Transdermal Scopolamine Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Transdermal Scopolamine Market Facts & Figures by Type
7.3 Europe Transdermal Scopolamine Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Transdermal Scopolamine by Region
8.1.1 Asia Pacific Transdermal Scopolamine Sales by Region
8.1.2 Asia Pacific Transdermal Scopolamine Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Transdermal Scopolamine Market Facts & Figures by Type
8.3 Asia Pacific Transdermal Scopolamine Market Facts & Figures by Application

9 Latin America
9.1 Latin America Transdermal Scopolamine by Country
9.1.1 Latin America Transdermal Scopolamine Sales by Country
9.1.2 Latin America Transdermal Scopolamine Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Transdermal Scopolamine Market Facts & Figures by Type
9.3 Central & South America Transdermal Scopolamine Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Transdermal Scopolamine by Country
10.1.1 Middle East and Africa Transdermal Scopolamine Sales by Country
10.1.2 Middle East and Africa Transdermal Scopolamine Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 UAE
10.2 Middle East and Africa Transdermal Scopolamine Market Facts & Figures by Type
10.3 Middle East and Africa Transdermal Scopolamine Market Facts & Figures by Application

11 Company Profiles
11.1 Baxter International Inc.
11.1.1 Baxter International Inc. Corporation Information
11.1.2 Baxter International Inc. Description and Business Overview
11.1.3 Baxter International Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Baxter International Inc. Transdermal Scopolamine Products Offered
11.1.5 Baxter International Inc. Related Developments
11.2 GlaxoSmithKline plc
11.2.1 GlaxoSmithKline plc Corporation Information
11.2.2 GlaxoSmithKline plc Description and Business Overview
11.2.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline plc Transdermal Scopolamine Products Offered
11.2.5 GlaxoSmithKline plc Related Developments
11.3 Novartis AG
11.3.1 Novartis AG Corporation Information
11.3.2 Novartis AG Description and Business Overview
11.3.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis AG Transdermal Scopolamine Products Offered
11.3.5 Novartis AG Related Developments
11.4 Perrigo Company plc.
11.4.1 Perrigo Company plc. Corporation Information
11.4.2 Perrigo Company plc. Description and Business Overview
11.4.3 Perrigo Company plc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Perrigo Company plc. Transdermal Scopolamine Products Offered
11.4.5 Perrigo Company plc. Related Developments
11.5 Caleb Pharmaceuticals, Inc.
11.5.1 Caleb Pharmaceuticals, Inc. Corporation Information
11.5.2 Caleb Pharmaceuticals, Inc. Description and Business Overview
11.5.3 Caleb Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Products Offered
11.5.5 Caleb Pharmaceuticals, Inc. Related Developments
11.6 Myungmoon Pharma Co. LTD.
11.6.1 Myungmoon Pharma Co. LTD. Corporation Information
11.6.2 Myungmoon Pharma Co. LTD. Description and Business Overview
11.6.3 Myungmoon Pharma Co. LTD. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Myungmoon Pharma Co. LTD. Transdermal Scopolamine Products Offered
11.6.5 Myungmoon Pharma Co. LTD. Related Developments
11.1 Baxter International Inc.
11.1.1 Baxter International Inc. Corporation Information
11.1.2 Baxter International Inc. Description and Business Overview
11.1.3 Baxter International Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Baxter International Inc. Transdermal Scopolamine Products Offered
11.1.5 Baxter International Inc. Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Transdermal Scopolamine Market Estimates and Projections by Region
12.1.1 Global Transdermal Scopolamine Sales Forecast by Regions 2021-2026
12.1.2 Global Transdermal Scopolamine Revenue Forecast by Regions 2021-2026
12.2 North America Transdermal Scopolamine Market Size Forecast (2021-2026)
12.2.1 North America: Transdermal Scopolamine Sales Forecast (2021-2026)
12.2.2 North America: Transdermal Scopolamine Revenue Forecast (2021-2026)
12.2.3 North America: Transdermal Scopolamine Market Size Forecast by Country (2021-2026)
12.3 Europe Transdermal Scopolamine Market Size Forecast (2021-2026)
12.3.1 Europe: Transdermal Scopolamine Sales Forecast (2021-2026)
12.3.2 Europe: Transdermal Scopolamine Revenue Forecast (2021-2026)
12.3.3 Europe: Transdermal Scopolamine Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Transdermal Scopolamine Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Transdermal Scopolamine Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Transdermal Scopolamine Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Transdermal Scopolamine Market Size Forecast by Region (2021-2026)
12.5 Latin America Transdermal Scopolamine Market Size Forecast (2021-2026)
12.5.1 Latin America: Transdermal Scopolamine Sales Forecast (2021-2026)
12.5.2 Latin America: Transdermal Scopolamine Revenue Forecast (2021-2026)
12.5.3 Latin America: Transdermal Scopolamine Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Transdermal Scopolamine Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Transdermal Scopolamine Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Transdermal Scopolamine Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Transdermal Scopolamine Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Transdermal Scopolamine Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Transdermal Scopolamine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Transdermal Scopolamine Market Segments
Table 2. Ranking of Global Top Transdermal Scopolamine Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Transdermal Scopolamine Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Tablet Type
Table 5. Major Manufacturers of Syrups Type
Table 6. Major Manufacturers of Injections Type
Table 7. Major Manufacturers of Patch Type
Table 8. Major Manufacturers of Gel Type
Table 9. Global Transdermal Scopolamine Market Size Growth Rate by Application 2020-2026 (K Units)
Table 10. Global Transdermal Scopolamine Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 11. Global Transdermal Scopolamine Sales by Regions 2015-2020 (K Units)
Table 12. Global Transdermal Scopolamine Sales Market Share by Regions (2015-2020)
Table 13. Global Transdermal Scopolamine Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Transdermal Scopolamine Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global Transdermal Scopolamine Sales Share by Manufacturers (2015-2020)
Table 16. Global Transdermal Scopolamine Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Transdermal Scopolamine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Transdermal Scopolamine as of 2019)
Table 18. Transdermal Scopolamine Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Transdermal Scopolamine Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Transdermal Scopolamine Price (2015-2020) (USD/Unit)
Table 21. Transdermal Scopolamine Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Transdermal Scopolamine Product Type
Table 23. Date of International Manufacturers Enter into Transdermal Scopolamine Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Transdermal Scopolamine Sales by Type (2015-2020) (K Units)
Table 26. Global Transdermal Scopolamine Sales Share by Type (2015-2020)
Table 27. Global Transdermal Scopolamine Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Transdermal Scopolamine Revenue Share by Type (2015-2020)
Table 29. Transdermal Scopolamine Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global Transdermal Scopolamine Sales by Application (2015-2020) (K Units)
Table 31. Global Transdermal Scopolamine Sales Share by Application (2015-2020)
Table 32. North America Transdermal Scopolamine Sales by Country (2015-2020) (K Units)
Table 33. North America Transdermal Scopolamine Sales Market Share by Country (2015-2020)
Table 34. North America Transdermal Scopolamine Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Transdermal Scopolamine Revenue Market Share by Country (2015-2020)
Table 36. North America Transdermal Scopolamine Sales by Type (2015-2020) (K Units)
Table 37. North America Transdermal Scopolamine Sales Market Share by Type (2015-2020)
Table 38. North America Transdermal Scopolamine Sales by Application (2015-2020) (K Units)
Table 39. North America Transdermal Scopolamine Sales Market Share by Application (2015-2020)
Table 40. Europe Transdermal Scopolamine Sales by Country (2015-2020) (K Units)
Table 41. Europe Transdermal Scopolamine Sales Market Share by Country (2015-2020)
Table 42. Europe Transdermal Scopolamine Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Transdermal Scopolamine Revenue Market Share by Country (2015-2020)
Table 44. Europe Transdermal Scopolamine Sales by Type (2015-2020) (K Units)
Table 45. Europe Transdermal Scopolamine Sales Market Share by Type (2015-2020)
Table 46. Europe Transdermal Scopolamine Sales by Application (2015-2020) (K Units)
Table 47. Europe Transdermal Scopolamine Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Transdermal Scopolamine Sales by Region (2015-2020) (K Units)
Table 49. Asia Pacific Transdermal Scopolamine Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Transdermal Scopolamine Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Transdermal Scopolamine Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Transdermal Scopolamine Sales by Type (2015-2020) (K Units)
Table 53. Asia Pacific Transdermal Scopolamine Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Transdermal Scopolamine Sales by Application (2015-2020) (K Units)
Table 55. Asia Pacific Transdermal Scopolamine Sales Market Share by Application (2015-2020)
Table 56. Latin America Transdermal Scopolamine Sales by Country (2015-2020) (K Units)
Table 57. Latin America Transdermal Scopolamine Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Transdermal Scopolamine Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Transdermal Scopolamine Revenue Market Share by Country (2015-2020)
Table 60. Latin America Transdermal Scopolamine Sales by Type (2015-2020) (K Units)
Table 61. Latin America Transdermal Scopolamine Sales Market Share by Type (2015-2020)
Table 62. Latin America Transdermal Scopolamine Sales by Application (2015-2020) (K Units)
Table 63. Latin America Transdermal Scopolamine Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Transdermal Scopolamine Sales by Country (2015-2020) (K Units)
Table 65. Middle East and Africa Transdermal Scopolamine Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Transdermal Scopolamine Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Transdermal Scopolamine Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Transdermal Scopolamine Sales by Type (2015-2020) (K Units)
Table 69. Middle East and Africa Transdermal Scopolamine Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Transdermal Scopolamine Sales by Application (2015-2020) (K Units)
Table 71. Middle East and Africa Transdermal Scopolamine Sales Market Share by Application (2015-2020)
Table 72. Baxter International Inc. Corporation Information
Table 73. Baxter International Inc. Description and Major Businesses
Table 74. Baxter International Inc. Transdermal Scopolamine Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 75. Baxter International Inc. Product
Table 76. Baxter International Inc. Recent Development
Table 77. GlaxoSmithKline plc Corporation Information
Table 78. GlaxoSmithKline plc Description and Major Businesses
Table 79. GlaxoSmithKline plc Transdermal Scopolamine Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. GlaxoSmithKline plc Product
Table 81. GlaxoSmithKline plc Recent Development
Table 82. Novartis AG Corporation Information
Table 83. Novartis AG Description and Major Businesses
Table 84. Novartis AG Transdermal Scopolamine Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Novartis AG Product
Table 86. Novartis AG Recent Development
Table 87. Perrigo Company plc. Corporation Information
Table 88. Perrigo Company plc. Description and Major Businesses
Table 89. Perrigo Company plc. Transdermal Scopolamine Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Perrigo Company plc. Product
Table 91. Perrigo Company plc. Recent Development
Table 92. Caleb Pharmaceuticals, Inc. Corporation Information
Table 93. Caleb Pharmaceuticals, Inc. Description and Major Businesses
Table 94. Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Caleb Pharmaceuticals, Inc. Product
Table 96. Caleb Pharmaceuticals, Inc. Recent Development
Table 97. Myungmoon Pharma Co. LTD. Corporation Information
Table 98. Myungmoon Pharma Co. LTD. Description and Major Businesses
Table 99. Myungmoon Pharma Co. LTD. Transdermal Scopolamine Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Myungmoon Pharma Co. LTD. Product
Table 101. Myungmoon Pharma Co. LTD. Recent Development
Table 102. Global Transdermal Scopolamine Sales Forecast by Regions (2021-2026) (K Units)
Table 103. Global Transdermal Scopolamine Sales Market Share Forecast by Regions (2021-2026)
Table 104. Global Transdermal Scopolamine Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 105. Global Transdermal Scopolamine Revenue Market Share Forecast by Regions (2021-2026)
Table 106. North America: Transdermal Scopolamine Sales Forecast by Country (2021-2026) (K Units)
Table 107. North America: Transdermal Scopolamine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 108. Europe: Transdermal Scopolamine Sales Forecast by Country (2021-2026) (K Units)
Table 109. Europe: Transdermal Scopolamine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Asia Pacific: Transdermal Scopolamine Sales Forecast by Region (2021-2026) (K Units)
Table 111. Asia Pacific: Transdermal Scopolamine Revenue Forecast by Region (2021-2026) (US$ Million)
Table 112. Latin America: Transdermal Scopolamine Sales Forecast by Country (2021-2026) (K Units)
Table 113. Latin America: Transdermal Scopolamine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 114. Middle East and Africa: Transdermal Scopolamine Sales Forecast by Country (2021-2026) (K Units)
Table 115. Middle East and Africa: Transdermal Scopolamine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 116. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 117. Key Challenges
Table 118. Market Risks
Table 119. Main Points Interviewed from Key Transdermal Scopolamine Players
Table 120. Transdermal Scopolamine Customers List
Table 121. Transdermal Scopolamine Distributors List
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Transdermal Scopolamine Product Picture
Figure 2. Global Transdermal Scopolamine Sales Market Share by Type in 2020 & 2026
Figure 3. Tablet Type Product Picture
Figure 4. Syrups Type Product Picture
Figure 5. Injections Type Product Picture
Figure 6. Patch Type Product Picture
Figure 7. Gel Type Product Picture
Figure 8. Global Transdermal Scopolamine Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Ambulance Center
Figure 12. Others
Figure 13. Transdermal Scopolamine Report Years Considered
Figure 14. Global Transdermal Scopolamine Market Size 2015-2026 (US$ Million)
Figure 15. Global Transdermal Scopolamine Sales 2015-2026 (K Units)
Figure 16. Global Transdermal Scopolamine Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Transdermal Scopolamine Sales Market Share by Region (2015-2020)
Figure 18. Global Transdermal Scopolamine Sales Market Share by Region in 2019
Figure 19. Global Transdermal Scopolamine Revenue Market Share by Region (2015-2020)
Figure 20. Global Transdermal Scopolamine Revenue Market Share by Region in 2019
Figure 21. Global Transdermal Scopolamine Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Transdermal Scopolamine Revenue in 2019
Figure 23. Transdermal Scopolamine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Transdermal Scopolamine Sales Market Share by Type (2015-2020)
Figure 25. Global Transdermal Scopolamine Sales Market Share by Type in 2019
Figure 26. Global Transdermal Scopolamine Revenue Market Share by Type (2015-2020)
Figure 27. Global Transdermal Scopolamine Revenue Market Share by Type in 2019
Figure 28. Global Transdermal Scopolamine Market Share by Price Range (2015-2020)
Figure 29. Global Transdermal Scopolamine Sales Market Share by Application (2015-2020)
Figure 30. Global Transdermal Scopolamine Sales Market Share by Application in 2019
Figure 31. Global Transdermal Scopolamine Revenue Market Share by Application (2015-2020)
Figure 32. Global Transdermal Scopolamine Revenue Market Share by Application in 2019
Figure 33. North America Transdermal Scopolamine Sales Growth Rate 2015-2020 (K Units)
Figure 34. North America Transdermal Scopolamine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Transdermal Scopolamine Sales Market Share by Country in 2019
Figure 36. North America Transdermal Scopolamine Revenue Market Share by Country in 2019
Figure 37. U.S. Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 38. U.S. Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 40. Canada Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Transdermal Scopolamine Market Share by Type in 2019
Figure 42. North America Transdermal Scopolamine Market Share by Application in 2019
Figure 43. Europe Transdermal Scopolamine Sales Growth Rate 2015-2020 (K Units)
Figure 44. Europe Transdermal Scopolamine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Transdermal Scopolamine Sales Market Share by Country in 2019
Figure 46. Europe Transdermal Scopolamine Revenue Market Share by Country in 2019
Figure 47. Germany Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 48. Germany Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 50. France Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 52. U.K. Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 54. Italy Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 56. Russia Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Transdermal Scopolamine Market Share by Type in 2019
Figure 58. Europe Transdermal Scopolamine Market Share by Application in 2019
Figure 59. Asia Pacific Transdermal Scopolamine Sales Growth Rate 2015-2020 (K Units)
Figure 60. Asia Pacific Transdermal Scopolamine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Transdermal Scopolamine Sales Market Share by Region in 2019
Figure 62. Asia Pacific Transdermal Scopolamine Revenue Market Share by Region in 2019
Figure 63. China Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 64. China Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 66. Japan Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 68. South Korea Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 70. India Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 72. Australia Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 74. Taiwan Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 76. Indonesia Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 78. Thailand Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 80. Malaysia Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 82. Philippines Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 84. Vietnam Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Transdermal Scopolamine Market Share by Type in 2019
Figure 86. Asia Pacific Transdermal Scopolamine Market Share by Application in 2019
Figure 87. Latin America Transdermal Scopolamine Sales Growth Rate 2015-2020 (K Units)
Figure 88. Latin America Transdermal Scopolamine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Transdermal Scopolamine Sales Market Share by Country in 2019
Figure 90. Latin America Transdermal Scopolamine Revenue Market Share by Country in 2019
Figure 91. Mexico Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 92. Mexico Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 94. Brazil Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 96. Argentina Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Transdermal Scopolamine Market Share by Type in 2019
Figure 98. Latin America Transdermal Scopolamine Market Share by Application in 2019
Figure 99. Middle East and Africa Transdermal Scopolamine Sales Growth Rate 2015-2020 (K Units)
Figure 100. Middle East and Africa Transdermal Scopolamine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Transdermal Scopolamine Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Transdermal Scopolamine Revenue Market Share by Country in 2019
Figure 103. Turkey Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 104. Turkey Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 106. Saudi Arabia Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. UAE Transdermal Scopolamine Sales Growth Rate (2015-2020) (K Units)
Figure 108. UAE Transdermal Scopolamine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Transdermal Scopolamine Market Share by Type in 2019
Figure 110. Middle East and Africa Transdermal Scopolamine Market Share by Application in 2019
Figure 111. North America Transdermal Scopolamine Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. North America Transdermal Scopolamine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Transdermal Scopolamine Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Europe Transdermal Scopolamine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Transdermal Scopolamine Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Asia Pacific Transdermal Scopolamine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Transdermal Scopolamine Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Latin America Transdermal Scopolamine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Transdermal Scopolamine Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 120. Middle East and Africa Transdermal Scopolamine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed